RNA, U6atac small nuclear 9, pseudogeneGenealiases: []
Q-omics provides the consensus-scored RNU6ATAC9P profile across patient tissues and cancer cell-line models. RNU6ATAC9P expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in THCA. Among the 18 cancer types available for tumor–normal comparison, RNU6ATAC9P is differentially expressed in 5, with the highest sampling consensus in KICH. Additionally, RNU6ATAC9P RNA expression shows 8,770 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight THCA, KICH, and THYM as cancer lineages where RNU6ATAC9P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNU6ATAC9P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNU6ATAC9P survival associations across molecular data types. RNU6ATAC9P RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNU6ATAC9P RNA expression–survival associations across cancer types. High RNU6ATAC9P expression shows unfavorable associations in THCA, BLCA, DLBC, LUSC and KICH, but favorable associations in LUAD. The THCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify THCA as the clearest survival context for RNU6ATAC9P RNA expression.
This table summarizes RNU6ATAC9P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for RNU6ATAC9P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNU6ATAC9P shows lower tumor expression in THCA and higher tumor expression in KICH, STAD, COAD and BRCA. The KICH box plot shows higher RNU6ATAC9P RNA expression in tumor versus normal tissue (log2 FC = +0.169, t-test p = .021).
This table shows molecular features associated with RNU6ATAC9P in patient tissues and cancer cell lines. In patient samples, RNU6ATAC9P shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
